LANDMARK DEAL FOR UQ-TRINITY INFLAMMATION START-UP

LANDMARK DEAL FOR UQ-TRINITY INFLAMMATION START-UP

A start-up company developing treatments for inflammatory diseases based on a research partnership between The University of Queensland and Trinity College Dublin (TCD) has been acquired in a landmark deal – one of the largest in Australian and Irish biotech history.

Inflazome has been acquired by Roche for an upfront cash payment of €380 million (about $A617 million), plus additional payments based on the achievement of certain milestones.

The IP behind Inflazome’s drug candidates is based on a research partnership between Professor Matt Cooper, Professor Kate Schroder, Dr Rebecca Coll and Professor Avril Robertson from UQ’s Institute for Molecular Bioscience and Professor Luke O’Neill from Trinity College Dublin.

View Article

    • Category: News
    • Date: September 22, 2020
    • Added By: ImagingCoE

Related Projects